ScholarLens Back to search
2013•European Journal of CancerRequires access

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

Ki Hyeong Lee, Jung Shin Lee, Sang‐We Kim, José Rodrigues-Pereira, Baohui Han, Xiangqun Song, Jie Wang, Hoon-Kyo Kim, Tarini Prasad Sahoo, Raghunadharao Digumarti, Xin Wang, Sedat Altuǧ, Mauro Orlando

Open publisher page 77 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 77 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Pemetrexed, Erlotinib, Medicine, Oncology, Lung cancer, Internal medicine, Second line treatment, Phases of clinical research

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer — Research Paper | ScholarLens